CymaBay Therapeutics Email Format

Pharmaceutical ManufacturingCalifornia, United States51-200 Employees

We are a clinical-stage biopharmaceutical company focused on developing and providing access to innovative therapies for patients with liver and other chronic diseases with high unmet medical need.

Seladelpar is a potent, selective, orally active PPARδ agonist in development for the treatment of patients with the autoimmune liver disease, primary biliary cholangitis (PBC).

Our pipeline also includes additional investigational products and lead candidates for liver and other chronic diseases.

✕

Access Insights for CymaBay Therapeutics and Millions of Other Companies

Sign up for full access to CymaBay Therapeutics information.

Continue with GoogleContinue with Microsoft

No credit card needed

OR

Work email

Create AccountBy creating an account, you agree to LeadIQ's Terms of Use and Privacy Policy.

Sign up for free to view info

Company overview Employee directory